These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension. Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561 [TBL] [Abstract][Full Text] [Related]
3. Selective aldosterone blockade with eplerenone in patients with congestive heart failure. Salam AM Expert Opin Investig Drugs; 2003 Aug; 12(8):1423-7. PubMed ID: 12882627 [TBL] [Abstract][Full Text] [Related]
4. ARAs to the RESCUE. Kaplan NM J Am Soc Hypertens; 2016 Mar; 10(3):187-8. PubMed ID: 27408946 [No Abstract] [Full Text] [Related]
5. Hypertension, angiotensin II, aldosterone, and race. Ben-Yehuda O J Am Coll Cardiol; 2003 Apr; 41(7):1156-8. PubMed ID: 12679216 [No Abstract] [Full Text] [Related]
6. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. George J; Struthers AD Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264 [TBL] [Abstract][Full Text] [Related]
7. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Karagiannis A; Athyros VG; Mikhailidis DP Clin Cardiol; 2009 Apr; 32(4):230. PubMed ID: 19353701 [No Abstract] [Full Text] [Related]
8. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167 [No Abstract] [Full Text] [Related]
9. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153 [TBL] [Abstract][Full Text] [Related]
10. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists. Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661 [TBL] [Abstract][Full Text] [Related]